alexa Long-Term Remissions With Use of High Dose Cyclophospha
ISSN: 2376-0389

Journal of Multiple Sclerosis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Long-Term Remissions With Use of High Dose Cyclophosphamide in Multiple Sclerosis

Bilgiç AB1*, Börü UT1, Taşdemir M2, Alp SI3, Alp R4, Yıldırım S1, Duman A1, Güler N1 and Kurtzke JF5

1Lütfi Kirdar Kartal Training and Research Hospital, Department of Neurology, Istanbul, Turkey

2Marmara University, School of Medicine, Department of Public Health, Istanbul, Turkey

3Tekirdağ Çorlu State Hospital, Department of Neurology, Tekirdağ, Turkey

4Tekirdağ Namık Kemal University, Department of Neurology, Tekirdağ, Turkey

5Georgetown University, Department of Neurology, Washington DC, USA

*Corresponding Author:
Bilgic AB
Lütfi Kirdar Kartal Training and Research Hospital
İstanbul, Turkey
Tel: 00902164413900
E-mail: [email protected]

Received date: May 04, 2016; Accepted date: October 20, 2016; Published date: October 27, 2016

Citation: Bilgiç AB, Börü UT, Taşdemir M, Alp SI, Alp R, et al. (2016) Long-Term Remissions With Use of High Dose Cyclophosphamide in Multiple Sclerosis. J Mult Scler (Foster City) 3:185. doi:10.4172/2376-0389.1000185

Copyright: © 2016 Bilgiç AB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: In this study, the results of high dose intravenous monthly pulse CYC on patients with worsening relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) were evaluated. Methods: Fifty-six patients who presented with worsening RRMS (30) or SPMS (26) were to be treated with intravenous (IV) monthly pulse of 800 mg/m² CYC in the first year and bimonthly in the second year. We evaluated the results before treatment and after 12 and 24 months. Results: In the RRMS patients, after 2 years baseline EDSS had improved in 18, was unchanged in 5 and worse in 3. In RRMS group annual relapse rate was 0.92 at the beginning. it decreased to 0.23 in first year and to 0.23 in second year. The SPMS patients after 2 years baseline EDSS had improved in 5, was unchanged in 15 and worse in 3. In SPMS group annual relapse rate was 0.26 at the beggining. It decreased 0.13 in the first year and 0.04 in the second year. Conclusion: This study showed that high dose CYC treatment for two years was well tolerated and seemed effective for both RRMS and SPMS.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords